Article Text
PostScript
Letter
Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes
Statistics from Altmetric.com
Footnotes
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.